文献速递中毒与环境急症消化、代谢与肾脏急症

阿片或兴奋剂过量患者中隐匿性溴唑仑暴露

Occult bromazolam exposure in patients presenting with opioid or stimulant overdose.
PubMed 文献 · Clin Toxicol (Phila) · 2025-05-19
一句话结论7例未自述溴唑仑暴露的急性过量患者血中检出溴唑仑,所有镇静病例对纳洛酮有反应,无危重症或死亡。

该病例系列来自药物过量毒物监测报告项目,为多中心前瞻性项目,纳入13岁及以上疑似危及生命的阿片和/或兴奋剂过量患者,本系列取自其中单一急诊科,2023年6月至2024年1月共7例。患者均未自述溴唑仑使用,但全血检出溴唑仑,中位浓度29 µg/L(范围<5-84 µg/L)。临床表现为过度镇静(6/7)或激越(1/7),3例住院或急诊观察超过24小时,原因分别为晚期妊娠、镇静延长和需要社会服务。无患者入住重症监护室,全部存活;所有镇静病例对纳洛酮有反应,且无归因于溴唑仑的持续镇静。

要点

  • 7例疑似阿片和/或兴奋剂过量患者均未自述溴唑仑使用,但全血检出溴唑仑,中位浓度29 µg/L(范围<5-84 µg/L)。
  • 6例表现为过度镇静,1例表现为激越;所有镇静病例对纳洛酮有反应,且无归因于溴唑仑的持续镇静。
  • 3例住院或急诊观察超过24小时,原因分别为晚期妊娠、镇静延长和需要社会服务;无患者入住重症监护室,全部存活。
  • 作者认为,患者未知的物质存在于药物供应中;毒物监测项目对获取社区药物使用模式信息至关重要,这些信息无法从患者病史或医疗记录中获得。

适用人群与场景

  • 年龄13岁及以上、疑似危及生命的阿片和/或兴奋剂过量患者,纳入多中心前瞻性药物过量毒物监测报告项目,本病例系列取自其中单一急诊科。

研究设计与关键结果

  • 病例系列共7例,来自单一急诊科,纳入时间为2023年6月至2024年1月;患者均未自述溴唑仑暴露,但全血检出溴唑仑。
  • 临床表现:过度镇静6/7例,激越1/7例;中位血溴唑仑浓度29 µg/L(范围<5-84 µg/L)。
  • 3例住院或急诊观察超过24小时,原因分别为晚期妊娠、镇静延长和需要社会服务;无患者入住重症监护室,全部存活。
  • 所有镇静病例对纳洛酮有反应(所有病例均承认服用阿片,并经分析确认),无归因于检出溴唑仑的持续镇静。

证据类型、等级与局限

  • 证据类型:病例系列(多中心前瞻性项目中的单中心病例系列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,患者未知的物质存在于药物供应中;毒物监测项目对获取社区药物使用模式信息至关重要,这些信息无法从患者病史或医疗记录中获得。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Bromazolam is a benzodiazepine, not approved for use in any North American or European jurisdiction that has emerged as an adulterant in the United States illicit drug supply.

METHODS: This is a case series of seven patients treated for an acute overdose and found to have bromazolam in their blood despite no self-reported exposure. Patients were enrolled from June 2023 to January 2024 as part of the Drug Overdose Toxico-Surveillance Reporting Program, a multi-center, prospective project including patients aged 13 years and older with a suspected life-threatening opioid and/or stimulant overdose. This case series is drawn from a single emergency department from that project. Patients were interviewed on their drug use, and clinical data were collected from electronic medical records. Whole blood was obtained and tested qualitatively for over 1,200 psychoactive substances using liquid chromatography quadrupole time-of-flight mass spectrometry and quantitative measurements using liquid chromatography-tandem quadrupole mass spectrometry.

RESULTS: Patients presented with acute signs of excessive sedation (six of seven) or agitation (one of seven). The median blood bromazolam concentration was 29 µg/L (range <5-84 µg/L). Three patients were admitted to hospital or observed for more than 24 h in the emergency department. The reasons for admission/observation were advanced pregnancy, prolonged sedation, and the need for social services. No patients were placed in a critical care unit and all patients survived. During the structured interview, none of the patients reported bromazolam use.

DISCUSSION: This case series demonstrated no poor clinical outcomes in patients with acute overdose who had detectable bromazolam concentrations despite no reported bromazolam use. In all cases of sedation, patients responded to naloxone (in all cases the patients admitted to taking opioids, which was confirmed analytically), and there was no ongoing sedation attributed to the detected bromazolam.

CONCLUSIONS: Substances unknown to patients are present in the drug supply. Toxico-surveillance programs are essential to obtaining information about community patterns of drug use that cannot be obtained from patient history or from medical charts.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Cembellin-Kao A, Aldy K, Brent J, et al. Occult bromazolam exposure in patients presenting with opioid or stimulant overdose. Clin Toxicol (Phila). 2025. PMID: 40387680. doi:10.1080/15563650.2025.2490831

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。